Active Substance: human normal immunoglobulin (IVIg)
Common Name: human normal immunoglobulin (IVIg)
ATC Code: J06BA02
Marketing Authorisation Holder: CSL Behring GmbH
Active Substance: human normal immunoglobulin (IVIg)
Authorisation Date: 2008-04-25
Therapeutic Area: Immunologic Deficiency Syndromes Guillain-Barre Syndrome Bone Marrow Transplantation Purpura, Thrombocytopenic, Idiopathic Mucocutaneous Lymph Node Syndrome
Pharmacotherapeutic Group: Immune sera and immunoglobulins
Replacement therapy in adults, and children and adolescents (0-18 years) in:
- primary immunodeficiency (PID) syndromes with impaired antibody production;
- hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed;
- hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who have failed to respond to pneumococcal immunisation;
- hypogammaglobulinaemia in patients after allogeneic haematopoietic-stem-cell transplantation (HSCT);
- congenital AIDS with recurrent bacterial infections.
Immunomodulation in adults, and children and adolescents (0-18 years) in:
- primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;
- Guillain-Barré syndrome;
- Kawasaki disease;
- chronic inflammatory demyelinating polyneuropathy (CIDP). Only limited experience is available of use of intravenous immunoglobulins in children with CIDP.
What is Privigen?
Privigen is a medicine that contains the active substance human normal immunoglobulin. It is available as a solution for infusion (drip) into a vein (100 mg/ml).
What is Privigen used for?
Privigen is used in three main groups of patients:
- Patients who are at risk of infection because they do not have sufficient antibodies (proteins naturally found in the blood that help the body to fight infections and other diseases). These can be people who are born with a lack of antibodies (primary immunodeficiency syndrome, PID). It also includes patients whose lack of antibodies is due to a cancer of the blood (myeloma or chronic lymphoid leukaemia) or children born with acquired immune deficiency syndrome (AIDS), who suffer from frequent infections. These types of conditions are called ‘immunodeficiency syndromes’ and their treatment is called ‘replacement therapy’.
- Patients with certain immune disorders. These patients have an abnormal immune system (the body’s defence system) that needs to be adjusted. They comprise patients with idiopathic thrombocytopenic purpura (ITP), who do not have enough platelets (components in the blood that help it to clot) and who are at high risk of bleeding; patients with Guillain-Barré syndrome or chronic inflammatory demyelinating polyneuropathy (CIDP), inflammatory disorders of the nerves that result in muscle weakness and numbness; and patients with Kawasaki disease, a disease mainly seen in children which causes inflammation of blood vessels. This type of treatment is called ‘immunomodulation’ (immune adjustment).
- Patients after allogeneic blood-stem-cell transplantation (a complex procedure where the patient receives stem cells from a matched donor to help restore the bone marrow).
The medicine can only be obtained with a prescription.
How is Privigen used?
Treatment with Privigen as a replacement therapy should be started and monitored by a doctor experienced in treating immunodeficiency syndrome.
Privigen is usually given as an infusion into a vein by a doctor or nurse. The dose and frequency of infusions (how often it is given) depend on the disease being treated. The dose may need to be adjusted for patients depending on their response.
For full details, see the summary of product characteristics (also part of the EPAR).
How does Privigen work?
The active substance in Privigen, human normal immunoglobulin, is a highly purified protein extracted from human plasma (part of the blood). It contains immunoglobulin G (IgG), which is a type of antibody. IgG has been used as a medicine since the 1980s and has a wide range of activity against organisms that can cause infection. Privigen works by restoring abnormally low IgG levels to their normal range in the blood. At higher doses, it can help to adjust an abnormal immune system and modulate the immune response.
How has Privigen been studied?
As human normal immunoglobulin has been used to treat these diseases for a long time, and in accordance with current guidelines, only three small studies were needed to establish the effectiveness and safety of Privigen in patients.
In the first study, Privigen was used as replacement therapy in 80 patients with PID, with the medicine being infused every three or four weeks. The main measure of effectiveness was the number of serious bacterial infections over a year’s treatment.
The second study looked at using Privigen for immunomodulation in 57 patients with ITP. Privigen was given on two consecutive days. The main measure of effectiveness was the highest blood platelet level that was achieved in the week after Privigen was given.
A third study examined the use of Privigen for immunomodulation in 28 patients with CIDP who were given Privigen every three weeks over a period of 24 weeks. The main measure of effectiveness was the number of patients who showed an improvement of at least 1 point on a 10-point scale of disability in their arms and legs.
Privigen was not compared to other treatments in the studies.
What benefit has Privigen shown during the studies?
In the first study, the patients had an average of 0.08 serious infections per year. Since this is below the predefined threshold of one infection per year, this indicates that the medicine is effective as replacement therapy.
In the second study, 46 (81%) of the 57 patients had a platelet count above 50 million platelets per millilitre at least once during the study.
This confirmed that Privigen is effective in immunomodulation.
In the third study, 17 (61%) of the 28 patients responded to treatment with an improvement of at least one point on the disability scale. The average improvement was about 1.4 points.
What is the risk associated with Privigen?
The most common side effects with Privigen (seen in more than 1 patient in 10) are headache, nausea, vomiting, diarrhoea, skin disorders (including rashes), pain (including in the back, neck, limbs, joints and face), fever, a flu-like illness, tiredness, weakness and pain at the injection site.
Some side effects are more likely with a high rate of infusion, in patients with low immunoglobulin levels, or in patients who have not received human normal immunoglobulin before or for a long time. For the full list of all side effects with Privigen, see the package leaflet.
Privigen must not be used in people who are hypersensitive (allergic) to normal human immunoglobulin or any of the other ingredients, or in patients who are allergic to other types of immunoglobulins, especially where they have deficiency (very low levels) of immunoglobulin A (IgA) and they have antibodies against IgA. Privigen must not be used in patients with hyperprolinaemia (a genetic disorder causing high levels of the amino acid proline in the blood).
Why has Privigen been approved?
The CHMP concluded that Privigen’s benefits are greater than its risks and recommended that it be given marketing authorisation.
What measures are being taken to ensure the safe use of Privigen?
A risk-management plan has been developed to ensure that Privigen is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Privigen, including the appropriate precautions to be followed by healthcare professionals and patients.
Haemolysis (breakdown of red blood cells) is an uncommon side effect in patients given human normal immunoglobulin (occurring with less than 1 dose in 100). Severe haemolysis seems to be slightly more frequent with Privigen than with some other products containing the same active substance. The company that markets Privigen will make some changes in the way it is produced and will carry out a study to monitor the effect of the changes.
Other information about Privigen
The European Commission granted a marketing authorisation valid throughout the European Union for Privigen on 25 April 2008.
For more information about treatment with Privigen, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.